RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Acute Promyelocytic Leukaemia: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Current management and emerging pharmacotherapeutic strategies in acute promyelocytic leukemia.
Laganà Alessandro et al., Expert opinion on pharmacotherapy (15 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42867330/
- 2.
Dynamic fibrinogen decline rate outperforms static admission values in predicting hematoma expansion in APL-related intracranial hemorrhage: a retrospective cohort study
Wentao Lai et al., Frontiers in Medicine (7 October 2026)
https://doi.org/10.3389/fmed.2026.1956224
- 3.
Fine-Needle Aspiration Cytology of Gingival Acute Promyelocytic Leukemia: Cytomorphologic Clues to an Unusual Extramedullary Presentation.
Radhakrishnan Aravind et al., Diagnostic cytopathology (3 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42828484/
- 4.
Acute Promyelocytic Leukemia With a Subgroup Exhibiting Basophilic Differentiation.
Su Zhan et al., International journal of laboratory hematology (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42071091/
- 5.
Quantitative single-cell analysis of PML-RARα oncogene-induced DNA damage along cell cycle progression.
Scalisi Silvia et al., Methods (San Diego, Calif.) (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42409088/
Clinical Trials : Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
NCT02339740 · Active (not recruiting) · Phase 3 · Children's Oncology Group
Ages 12 Months to 21
https://clinicaltrials.gov/study/NCT02339740
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Acute Promyelocytic Leukaemia
Acute promyelocytic leukaemia is a rare, fast-moving type of acute myeloid leukaemia in which immature white blood cells called promyelocytes build up in the bone marrow. It is caused by a change that fuses the PML and RARA genes, and it often causes serious bleeding problems. It is treated with all-trans retinoic acid and arsenic trioxide, sometimes with chemotherapy, and most people can be cured.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
INTRODUCTION: Acute promyelocytic leukemia (APL) has evolved from one of the most rapidly fatal neoplasms into the most curable acute myeloid leukemia subtype, following the sequential clinical introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Despite cure rates now approaching 100% in non-high-risk disease, early death occurring before or shortly after treatment initiation and relapse/refractory APL cases remain the principal obstacles to achieving a definitive cure. AREAS COVERED: This review summarizes current standard-of-care APL management, including risk stratification, induction, consolidation and maintenance strategies. It then reviews emerging pharmacotherapeutic strategies, including oral arsenic formulations, tamibarotene, anti-CD33 antibody-based and cellular therapies, and other investigational agents. A literature search of PubMed/MEDLINE was performed from the 1950s to 2026 using terms including 'acute promyelocytic leukemia,' 'ATRA,' 'arsenic trioxide,' 'oral arsenic,' 'tamibarotene,' 'gemtuzumab ozogamicin,' and other keywords, prioritizing recent randomized trials, prospective studies and expert consensus guidelines. EXPERT OPINION: Reducing early mortality through faster diagnostic suspicion, extending chemotherapy-free regimens to high-risk disease, and transitioning toward oral, outpatient-based arsenic formulations represent the most promising paths toward a definitive cure. Tailored strategies for rare variant and resistant APL subtypes, including targeted triplet combinations represent a promising treatment for complex APL case, but warrant structured evaluation in prospective clinical trials.
Common Questions
What is Acute Promyelocytic Leukaemia?
Acute promyelocytic leukaemia is a rare, fast-moving type of acute myeloid leukaemia in which immature white blood cells called promyelocytes build up in the bone marrow. It is caused by a change that fuses the PML and RARA genes, and it often causes serious bleeding problems. It is treated with all-trans retinoic acid and arsenic trioxide, sometimes with chemotherapy, and most people can be cured.
How many clinical trials are available for Acute Promyelocytic Leukaemia?
RareWays currently indexes 87 clinical trials for Acute Promyelocytic Leukaemia, of which 7 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Acute Promyelocytic Leukaemia come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Acute Promyelocytic Leukaemia.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.